Revision history of "GENERIC DIRECT ORAL ANTICOAGULANT DRUG FOR THROMBOEMBOLIC EVENTS" (Q3175983)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

9 October 2024

  • curprev 00:1300:13, 9 October 2024DG Regio talk contribs 64,697 bytes −6 Changed label, description and/or aliases in pt
  • curprev 00:1300:13, 9 October 2024DG Regio talk contribs 64,703 bytes −51 Set a claim value: summary (P836): Este projeto visa dar continuidade à política de desenvolvimento de especialidades farmacêuticas genéricas destinadas ao tratamento de patologias com elevado impacto socioeconómico e propõe o desenvolvimento de uma nova especialidade farmacêutica genérica de rivaroxabano, comprimidos revestidos de 10 mg, 15 mg e 20 mg, para a prevenção e tratamento de acontecimentos tromboembólicos em doentes adultos (tratamento de trombose venosa profunda e embolia...

7 March 2024

20 December 2023

12 June 2023

10 June 2023

4 August 2022

  • curprev 11:0211:02, 4 August 2022DG Regio talk contribs 62,400 bytes +41,433 Changed label, description and/or aliases in et, lt, hr, el, sk, fi, pl, hu, cs, lv, ga, sl, bg, mt, pt, da, ro, sv, nl, fr, de, it, es, and other parts: Adding translations: et, lt, hr, el, sk, fi, pl, hu, cs, lv, ga, sl, bg, mt, pt, da, ro, sv,

16 January 2022

17 December 2021

9 December 2021

4 December 2021

12 October 2021

  • curprev 18:3718:37, 12 October 2021DG Regio talk contribs 12,463 bytes +1,942 Created claim: summary (P836): This project aims to give continuity to the policy of development of generic proprietary medicinal products intended for the treatment of pathologies with high socio-economic impact, and proposes the development of a new generic proprietary medicinal product of rivaroxaban, 10 mg, 15 mg and 20 mg coated tablets, for the prevention and treatment of thromboembolic events in adult patients (treatment of deep venous thrombosis and pulmonary embolism...
  • curprev 18:3718:37, 12 October 2021DG Regio talk contribs 10,521 bytes −1,942 Removed claim: summary (P836): This project aims to give continuity to the policy of development of generic proprietary medicinal products intended for the treatment of pathologies with high socio-economic impact, and proposes the development of a new generic proprietary medicinal product of rivaroxaban, 10 mg, 15 mg and 20 mg coated tablets, for the prevention and treatment of thromboembolic events in adult patients (treatment of deep venous thrombosis and pulmonary emboli...
  • curprev 18:3118:31, 12 October 2021DG Regio talk contribs 12,463 bytes +123 Changed label, description and/or aliases in en: translated_label
  • curprev 18:3118:31, 12 October 2021DG Regio talk contribs 12,340 bytes +1,942 Created claim: summary (P836): This project aims to give continuity to the policy of development of generic proprietary medicinal products intended for the treatment of pathologies with high socio-economic impact, and proposes the development of a new generic proprietary medicinal product of rivaroxaban, 10 mg, 15 mg and 20 mg coated tablets, for the prevention and treatment of thromboembolic events in adult patients (treatment of deep venous thrombosis and pulmonary embolism...

10 October 2021

9 October 2021

8 October 2021